Coronavirus disease 2019 (COVID-19) and Long COVID

Chang, Yoon-Seok

doi:10.5415/apallergy.2022.12.e22

Cited by 5 publications

(5 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The outbreak of severe acute respiratory syndrome coronavirus 2 infection in 2019 has generated widespread interest in emerging viruses, such as avian H7N9 [23]. The use of MN to administer inactivated influenza vaccines against the H1N1, H3N2, and B strains was evaluated in a phase I clinical trial [24,25].…”

Section: Discussionmentioning

confidence: 99%

Transcutaneous immunization via dissolving microneedles protects mice from lethal influenza H7N9 virus challenge

Liu¹,

Yang²,

Li³

et al. 2022

Vaccine

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Transcutaneous immunization via dissolving microneedles protects mice from lethal influenza H7N9 virus challenge

Liu¹,

Yang²,

Li³

et al. 2022

Vaccine

View full text Add to dashboard Cite

“…In addition, the length of stay (A = 0.17, p = 1.82e-07; Fig 1D) and time to discharge or death (A = 0.15, p = 6.14e-07) also appear to be statistically significant (albeit weak) factors, with a longer median stay of 16 days (IQR [8,26]) seen in severe cases compared to 11 days (IQR [5,20]) in non-severe cases. In particular, we see a long tail for long stays for severe cases, as a result of patients who contracted severe, but non-fatal, COVID-19 and required a significant amount of recovery time.…”

Section: Plos Onementioning

confidence: 96%

“…Interestingly, whilst associated with ICU admission (A = 0.24, p = 1.15e-16) and intubation (A = 0.24, p = 5.61e-17), the admission NEWS2 score was not associated with patient death alone. The admission NEWS2 score shows median scores of 4 (IQR [1,8]) for severe cases and 3 (IQR [1,5]) for non-severe cases with a large amount of overlap between the distributions, indicating that the NEWS2 score at admission may not be a strong initial predictor of severe COVID-19.…”

Section: Associations With Disease Severitymentioning

confidence: 99%

“…At the time of writing, COVID-19 has resulted in over 625 million infections and 6.57 million deaths worldwide [4]. As well as this significant death toll, many survivors have suffered life-altering complications as a result of contracting the disease [5]. The COVID-19 pandemic has also resulted in significant social and economic disruption, including the biggest global recession since the Great Depression [6].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Combining viral genomics and clinical data to assess risk factors for severe COVID-19 (mortality, ICU admission, or intubation) amongst hospital patients in a large acute UK NHS hospital Trust

et al. 2023

View full text Add to dashboard Cite

Throughout the COVID-19 pandemic, valuable datasets have been collected on the effects of the virus SARS-CoV-2. In this study, we combined whole genome sequencing data with clinical data (including clinical outcomes, demographics, comorbidity, treatment information) for 929 patient cases seen at a large UK hospital Trust between March 2020 and May 2021. We identified associations between acute physiological status and three measures of disease severity; admission to the intensive care unit (ICU), requirement for intubation, and mortality. Whilst the maximum National Early Warning Score (NEWS2) was moderately associated with severe COVID-19 (A = 0.48), the admission NEWS2 was only weakly associated (A = 0.17), suggesting it is ineffective as an early predictor of severity. Patient outcome was weakly associated with myriad factors linked to acute physiological status and human genetics, including age, sex and pre-existing conditions. Overall, we found no significant links between viral genomics and severe outcomes, but saw evidence that variant subtype may impact relative risk for certain sub-populations. Specific mutations of SARS-CoV-2 appear to have little impact on overall severity risk in these data, suggesting that emerging SARS-CoV-2 variants do not result in more severe patient outcomes. However, our results show that determining a causal relationship between mutations and severe COVID-19 in the viral genome is challenging. Whilst improved understanding of the evolution of SARS-CoV-2 has been achieved through genomics, few studies on how these evolutionary changes impact on clinical outcomes have been seen due to complexities associated with data linkage. By combining viral genomics with patient records in a large acute UK hospital, this study represents a significant resource for understanding risk factors associated with COVID-19 severity. However, further understanding will likely arise from studies of the role of host genetics on disease progression.

show abstract

“…According to the World Health Organization, around 40 million Long COVID patients have been identi ed in Europe and the United States alone [1,2]. The Centers for Disease Control and Prevention (CDC), suggests the need to expand the evidence base to estimate both the risk of experiencing post-COVID conditions and the number of people experiencing them by demographic group [3]. Although there are grounds to believe that a genetic signature might be involved in Long COVID [4], to date no genetic markers have been reported.…”

Section: Introductionmentioning

confidence: 99%

Genomic Determinants of Long COVID

Corpas

Pintos²,

Moreno-Torres³

et al. 2023

Preprint

View full text Add to dashboard Cite

Around 5–10% of adults may experience persistence of symptoms/signs beyond 4 to 12 weeks after acute SARS-CoV-2 infection. According to the World Health Organization, up to 40 million people suffer from Long COVID in Europe and the USA alone. The Centers for Disease Control and Prevention have encouraged the recognition of predictors for Long COVID. Any genetic markers associated to the disease have remained elusive to date. Here we explore the potential contribution of genetic traits to Long COVID. We used a well characterized cohort of 50 individuals with definitive diagnostic criteria for Long COVID from an initial set of patients of more than 1,200 with suspected Long COVID. All were attended at Hospital Puerta de Hierro, a large regional hospital in Madrid, Spain. All subjects had tested positive for SARS-CoV-2 RNA and/or antibodies, showed clinical manifestations for more than 6 months, and developed more than 5 persistent symptoms/signs. Low pass whole genome sequencing was performed in blood specimens for our selected cohort. From hundreds of polygenic risk scores (PRS) recorded at the PGS Catalog, we tested in our selected cohort a total of 12 PRS that passed our filtering criteria. Selected PRS encompassed distinct medical conditions, including cancers, hematologic, cardiovascular, endocrine, immunologic and neurological disorders. The calculated PRS in our patients produced a distribution of scores that was compared to a control ancestry-matched general population. We found significant differences for the PRS of traits ‘Tiredness/lethargy in the last 2 weeks’ and suggestive significance for ‘Depression’ when comparing Long COVID patients and controls. Our results strongly support a genetic susceptibility for Long COVID, with those scoring high in genetic predisposition for ‘tiredness’ as more likely to develop the disease. Results shed new light into the physiopathological basis for Long COVID, contrary to opinions considering it a subjective condition.

show abstract

Coronavirus disease 2019 (COVID-19) and Long COVID

Cited by 5 publications

References 11 publications

Transcutaneous immunization via dissolving microneedles protects mice from lethal influenza H7N9 virus challenge

Transcutaneous immunization via dissolving microneedles protects mice from lethal influenza H7N9 virus challenge

Combining viral genomics and clinical data to assess risk factors for severe COVID-19 (mortality, ICU admission, or intubation) amongst hospital patients in a large acute UK NHS hospital Trust

Genomic Determinants of Long COVID

Contact Info

Product

Resources

About